Agency engagement · Program phases
How engagement works
An IntellaRx engagement runs scoping, then design, then a pilot, then evaluation and a decision on whether to continue, with the outcome measures agreed before the program starts.
Four phases, each with a defined output and a point at which either side can stop.
Phase one — scoping
A conversation with the people who would actually run the work. What is the population, what is the problem you are trying to move, what have you already tried, and what data do you already hold. The output is a written statement of the problem and an honest assessment of whether this program helps with it. Sometimes it does not, and saying so at this stage costs an agency nothing.
Phase two — design
Which components, for which population, with what data flows. This is where data governance gets settled, because your counsel needs a specific description of what moves where and not a general assurance. It is also where the outcome measures are agreed — before the program starts, and including the ones that could make it look bad.
Phase three — pilot
A defined population, a defined geography, a defined duration and a pre-registered set of measures. See pilot design for what makes a pilot capable of producing a real answer rather than a testimonial.
Phase four — evaluation and decision
The measures agreed in phase two, reported whatever they say, with the analysis available to the agency’s own epidemiologists. A pilot that does not work should be discontinued, and a program that cannot survive that possibility is not worth running.
What does IntellaRx need from an agency?
- A named clinical or public-health owner, not only a procurement contact. Programs without a clinical owner drift toward whatever is easiest to measure.
- A defined population and geography. “The state” is not a pilot.
- Agreed measures before the start, including negative ones.
- A route for participants to raise a problem and have it heard by someone who can change something.
- Your counsel’s determination on the applicable regimes, in writing, before any data moves.
What will IntellaRx not agree to?
- Deployments in which participation in the program is a condition of receiving treatment.
- Use of clinical components as an enforcement or case-building instrument.
- Individual-level reporting of behavioral health screening, social determinants assessment or monitoring data to an agency.
- Building a per-person suspicion score. See AI integrated rule discovery.
- Anything that would require IntellaRx to make a legal determination about your agency’s obligations.
The full boundary is on what we do and do not do.
Frequently asked questions
What happens in an IntellaRx pilot?
A pilot runs with a defined population, a defined geography, a defined duration and a pre-registered set of measures. Those measures are agreed in the design phase, before the program starts, including the ones that could make it look bad. That is what lets a pilot produce a real answer rather than a testimonial.
Can an agency stop the program after the pilot?
Yes. Each of the four phases has a defined output and a point at which either side can stop. In the evaluation phase the agreed measures are reported whatever they say, and the analysis is available to the agency’s own epidemiologists. A pilot that does not work should be discontinued.
When is data governance settled?
In phase two, design, before any data moves. Your counsel needs a specific description of what moves where, not a general assurance, so design fixes which components are used, for which population and with what data flows. IntellaRx also asks for counsel’s written determination on the applicable regimes before the start.
What if the program is not a fit for our agency?
Scoping says so. The first phase produces a written statement of the problem and an honest assessment of whether this program helps with it. Sometimes it does not, and hearing that at the scoping stage costs an agency nothing.